Medpace Holdings, Inc.

Medpace Holdings, Inc. is a global clinical research organization (CRO) specializing in the development and execution of clinical trials for pharmaceutical, biotechnology, and medical device companies. Founded in 1992 and headquartered in Cincinnati, Ohio, United States, Medpace provides comprehensive clinical development services across multiple therapeutic areas worldwide.

The company manages clinical trials from early-stage development through regulatory submission, offering services including Phase I–IV clinical research, clinical monitoring, regulatory affairs, medical writing, pharmacovigilance, biostatistics, clinical data management, and laboratory services.

Medpace has particular expertise in complex therapeutic areas such as oncology, cardiovascular diseases, metabolic disorders, neuroscience, immunology, and rare diseases. The company combines medical expertise, scientific knowledge, and operational capabilities to help sponsors efficiently design and execute clinical studies.

Unlike many traditional CRO models, Medpace integrates medical, regulatory, and operational teams within a unified structure, allowing closer collaboration throughout the clinical development process. Its global network includes research sites, investigators, and clinical professionals supporting studies across North America, Europe, Asia-Pacific, and other regions.

The company utilizes advanced clinical trial technologies and data-driven approaches to improve trial efficiency, patient recruitment, and study quality. Medpace follows international clinical research standards, including Good Clinical Practice (GCP), FDA regulations, EMA guidelines, and global quality requirements.

With more than three decades of experience, Medpace has become a trusted clinical research partner for emerging biotechnology companies, pharmaceutical organizations, and medical innovators seeking efficient and scientifically driven clinical trial solutions.